TARRYTOWN, N.Y., Oct. 24 /PRNewswire-FirstCall/ -- Emisphere
Technologies, Inc. (Nasdaq: EMIS) today announced that Gary Riley has been
appointed to the position of Vice President, Nonclinical Development and
Applied Biology, effective November 6, 2007. Dr. Riley will be responsible
for the oversight and management of nonclinical drug efficacy and safety
programs, including regulatory toxicology, and the strategic design of
discovery projects. Dr. Riley will report directly to Michael V. Novinski,
President and Chief Executive Officer. Emisphere Technologies, Inc. is a
biopharmaceutical company that focuses on a unique and improved delivery of
therapeutic molecules and pharmaceutical compounds using its eligen(R)
technology.
"Gary Riley has great hands-on experience in managing all aspects of
nonclinical drug development and in bringing issues before the FDA and
European Regulatory Agencies," said Michael V. Novinski, President and
Chief Executive Officer of Emisphere Technologies, Inc. "Dr. Riley also
brings a real expertise in integrating knowledge of the biological response
to novel drug delivery technologies and accelerating the product cycle. It
is a wealth of experience that we are excited to bring to Emisphere."
Dr. Riley has over 18 years experience as a nonclinical scientist and
manager in the biotechnology and pharmaceutical industries. He was the Vice
President of Toxicology and Applied Biology at Alkermes, Inc. in Cambridge,
Massachusetts, where he directed the design, execution and interpretation
of toxicology and nonclinical efficacy programs for a wide range of
parenteral drug delivery formulations. Dr. Riley played a key role in
obtaining FDA approvals for three novel controlled release formulations at
Alkermes in the past seven years, and has directed a large portfolio of
nonclinical safety programs for specialized drug formulations targeting CNS
diseases, reproduction, hematology, oncology and metabolic diseases. Dr.
Riley has also investigated the role of the host response on the
functionality of a variety of parenteral and inhalation drug delivery
formats.
His prior pharmaceutical experience includes his role as Director of
Pathobiology at Lederle Laboratories, where he designed and directed safety
assessment programs for product candidates to serve a broad range of
medical indications. Dr. Riley also has extensive experience in industrial
and government sponsored chemical toxicology research. In academia, he
formerly held faculty appointments in veterinary pathology at the
University of Illinois and Iowa State University.
"Emisphere is poised to make a significant difference in the lives of
millions of patients," said Dr. Riley. "It is an exciting time to join this
team and help move the Company to continued, greater success."
Dr. Riley is a veterinarian (BVSc, Sydney University) with graduate
qualifications in veterinary pathology (MVSc, Melbourne University and PhD,
University of Missouri). He is certified by the American College of
Veterinary Pathologists and the American Board of Toxicology. He is the
senior author of over 30 nonclinical IND and NDA submissions for the FDA
and EU drug registration agencies, and the author of over 30 peer-reviewed
publications.
Emisphere's broad-based drug delivery technology platform, known as the
eligen(R) technology, is based on the use of proprietary, synthetic
chemical compounds, known as Emisphere delivery agents, or "carriers."
Emisphere's eligen(R) technology makes it possible to deliver a therapeutic
molecule without altering its chemical form or biological integrity.
About Emisphere Technologies, Inc.
Emisphere Technologies, Inc. is a biopharmaceutical company that
focuses on a unique and improved delivery of therapeutic molecules and
pharmaceutical compounds using its eligen(R) technology. These molecules
and compounds could be currently available or are in pre-clinical or
clinical development. Such molecules or compounds usually cannot be
delivered by the oral route of administration or the benefits of these
compounds are limited due to poor bioavailability, slow on-set of action or
variable absorption. The eligen(R) technology can be applied to the oral
route of administration as well other delivery pathways, such as buccal,
per rectum, pulmonary, intra-vaginal or transdermal. The Web site is:
http://www.emisphere.com.
Safe Harbor Statement Regarding Forward-Looking Statements
The statements in this release and oral statements made by
representatives of Emisphere relating to matters that are not historical
facts (including without limitation those regarding future performance or
financial results, the timing or potential outcomes of research
collaborations or clinical trials, any market that might develop for any of
Emisphere's product candidates and the sufficiency of Emisphere's cash and
other capital resources) are forward-looking statements that involve risks
and uncertainties, including, but not limited to, the likelihood that
actual performance or results could materially differ, that future research
will prove successful, the likelihood that any product in the research
pipeline will receive regulatory approval in the United States or abroad,
the ability of Emisphere and/or its partners to develop, manufacture and
commercialize products using Emisphere's drug delivery technology, or
Emisphere's ability to fund such efforts with or without partners.
Emisphere undertakes no obligation to update any of these statements.
Readers are cautioned not to place undue reliance on these forward-looking
statements, which speak only as to the date hereof. Accordingly any
forward-looking statements should be read in conjunction with the
additional risks and uncertainties detailed in Emisphere's filings with the
Securities and Exchange Commission, including those factors discussed under
the caption "Risk Factors" in Emisphere's Annual Report on Form 10-K (file
no. 000-17758) filed on March 6, 2007, and our Quarterly Report on Form
10-Q for the quarter ended March 31, 2007, filed on May 7, 2007 (file no.
000-17758).
SOURCE Emisphere Technologies, Inc.
 back to top
Related links:
http://www.emisphere.com/
CONTACT:
Bob Madison, Corporate Communications,
+1-914-593-8360
|
